Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals

Cancer Immunology Immunotherapy

Volumn 48, Issue 10, 2000, Pages 550-560

  Kjærgaard, Jørgen ^a   Hokland, Marianne E ^b   Agger, Ralf ^b   Skovbo, Anni ^b   Nannmark, Ulf ^b   Basse, Per H ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; B16 melanoma; Biodistribution; Route of injection; T LAK cells

Indexed keywords

FLUORESCENT DYE; LYMPHOKINE;

ADOPTIVE IMMUNOTHERAPY; ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BRAIN; CANCER; CELL LABELING; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FLUORESCENCE MICROSCOPY; KIDNEY; LIVER; LUNG; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NONHUMAN; OVARY; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE ACTIVATION;

EID: 0006495389     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00006673     Document Type: Article

References (36)

1. 1. Bar MH, Sznol M, Atkins MB (1990) Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 8:1138
2. 2. Basse P, Hokland P, Heron I, Hokland M (1988) Fate of tumor cells injected into left ventricle of heart in BALB/c mice: role of natural killer cells. J Natl Cancer Inst 80:657
3. 3. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH (1991) Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 174:479
4. 4. Basse PH, Goldfarb RH, Herberman RB, Hokland M (1994) Accumulation of adoptively transferred A-NK cells in murine metastases: kinetics and role of IL-2. In vivo 8:17
5. 5. Brubaker J, Chong K, Welsh R (1991) Lymphokine-activated killer cells are rejected in vivo by activated natural killer cells. J Immunol 147:1439
6. 6. Bryand BJ, Cole LJ (1967) Evidence for pluripotentiality of marrow stem cells: modification of tissue distribution of in vivo 125-IUdR labeled transplanted marrow. In: The lymphocyte in immunology and haemopoiesis. London, p 170
7. 7. Cappuccini F, Lucci JA, Dett CA, Gatanaga M, Ininns EK, Gatanaga T, Yamamoto RS, Manetta A, DiSaia PJ, Granger GA (1992) Trafficking of syngeneic murine lymphokine activated killer T cells following intraperitoneal administration in normal and tumor bearing mice. Gynecol Oncol 46:163
8. 8. Donskov F, Basse PH, Hokland M (1996) Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue. Nat Immun 15:134
9. 9. Ettinghausen SE, Rosenberg SA (1986) Immunotherapy of murine sarcomas using lymphokine activated killer cells. Optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res 48:2784
10. 10. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823
11. 11. Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB, Gorelik E (1989) Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J Immunol 142:1748
12. 12. Hagenaars M, Ensink N, Koelemij R, Basse P, Eggermont A, Velde C van de, Fleuren G, Kuppen P (1998) Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration. Int J Cancer 75:233
13. 13. Herberman R, Basse P, Jain R (1990) Approaches to immunotherapy with defined population of IL-2 cultured NK cells, immune T cells or tumor infiltrating lymphocytes. In: Ress RC (ed) The biology and clinical applications of IL-2. Oxford University Press, Oxford, p 111
14. 14. Hughes WL, Commerford SLK, Gitlin D, Drueger RC, Schultz B, Sham V, Reilly P (1964) Deoxyribonucleic acid metabolism in vivo. I. Cell proliferation and cell death as measured by incorporation and elimination of iododeoxyuridine. Fed Proc 23:640
15. 15. Kjærgaard J, Shu S (1999) Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J Immunol (in press)
16. 16. Kjærgaard J, Hokland M, Nannmark U, Hokland P, Basse P (1998) Infiltration patterns of short-and long-term cultured A-NK and T-LAK cells following adoptive immunotherapy. Scand J Immunol 47:532
17. 17. Lafreniere R, Rosenberg SA (1985) Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 45:3735
18. 18. Lafreniere R, Rosenberg SA (1985) Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin-2 can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 135:4273
19. 19. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA (1981) Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor (TCGF). Cancer Res 41:4420
20. 20. Lucci JA, Manetta A, Cappuccini F, Ininns EK, Dett CA, DiSaia P, Yamamoto RS, Berman ML, Soopikian J, Granger GA (1992) Immunotherapy of ovarian cancer. II. In vitro generation and characterization of lymphokine-activated killer T cells from the peripheral blood of recurrent ovarian cancer patients. Gynecol Oncol 45:129
21. 21. Mulé JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225:1487
22. 22. Nannmark U, Basse P, Johansson BR, Kuppen P, Kjærgaard J, Hokland M (1996) Morphological studies of effector cell-microvessel interactions in adoptive immunotherapy in tumor-bearing animals. Nat Immun 15:78
23. 23. Paciucci PA, Holland JF, Glidewell O, Odchimar R (1989) Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2 activated cells in patients with advanced cancer. J Clin Oncol 7:869
24. 24. Papa MZ, Mule JJ, Rosenberg SA (1986) Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Cancer Res 46:4973
25. 25. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889
26. 26. Sasaki A, Jain RK, Maghazachi A, Goldfarb RH, Herberman RH (1989) Low deformability of lymphokine-activated killer cells as possible determinant of in vivo distribution (abstract). Cancer Res 49:3742
27. 27. Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ (1988) Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 48:5007
28. 28. Schwarz RE, Vujanovic NL, Hiserodt JC (1989) Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. Cancer Res 49:1441
29. 29. Shepard JH (1989) Surgical management of ovarian cancer. Clin Gynecol Oncol 187
30. 30. Shiloni E, Lafreniere R, Mule JJ, Schwarz SL, Rosenberg SA (1986) Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice. Cancer Res 46:5633
31. 31. Thompson JA, Lee DJ, Lindgren CG (1989) Influence of schedule of interleukin-2 administration on therapy with interleukin-2 and lymphokine activated killer cells. Cancer Res 49:235
32. 32. Vitolo D, Vujanovic N, Rabinowich H, Schlesinger M, Herberman R, Whiteside T (1993) Rapid interleukin-2 induced adherence of human natural killer (NK) cells accompanied by expression of mRNA for cytokines and IL-2 receptors. J Immunol 151:1926
33. 33. Weiss L, Nannmark U, Johansson BR, Bagge U (1992) Lethal deformation of cancer cells in the microcirculation: a potential rate regulator of hematogenous metastasis. Int J Cancer 50:103
34. 34. Wetterlin S, Aronsen FK, Bjorkman I (1977) Studies on methods for determination of the distribution of cardiac output in mice. Scand J Clin Lab Invest 37:451
35. 35. Yamamoto RS, Coss J, Vayuvegula B, Gupta S, Beamer Y, Jacques S, Jeffes EW, Carson WE, Jakowatz J, Granger GA (1991) Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma. J Immunol Methods 137:225
36. 36. Young RC, Chabner A, Hubbard SP (1978) Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 299:1261